IRIS
BALESTRIERI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 999
NA - Nord America 186
EU - Europa 113
AF - Africa 6
SA - Sud America 5
OC - Oceania 3
Totale 1.312
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 771
US - Stati Uniti d'America 168
CN - Cina 122
HK - Hong Kong 89
GB - Regno Unito 32
IT - Italia 28
DE - Germania 23
CA - Canada 11
IN - India 9
MX - Messico 7
NL - Olanda 6
PL - Polonia 4
UA - Ucraina 4
ZA - Sudafrica 4
AU - Australia 3
BR - Brasile 3
FR - Francia 3
JP - Giappone 3
SE - Svezia 3
AR - Argentina 2
AT - Austria 2
CZ - Repubblica Ceca 2
EG - Egitto 2
ES - Italia 2
FI - Finlandia 2
IR - Iran 2
BD - Bangladesh 1
LT - Lituania 1
SI - Slovenia 1
TH - Thailandia 1
TR - Turchia 1
Totale 1.312
Salva come PNG Salva come JPEG
Città #
Hong Kong 85
Singapore 76
Hefei 68
Ashburn 38
Boardman 30
London 27
Beijing 22
Shanghai 19
Rome 14
Council Bluffs 11
Munich 7
Los Angeles 6
Seattle 6
Toronto 6
Brooklyn 5
Mexico City 5
Nuremberg 5
San Francisco 5
Amsterdam 4
Pune 4
Warsaw 4
Chicago 3
Dallas 3
Hamburg 3
Markham 3
Paris 3
Phoenix 3
Santa Clara 3
Stockholm 3
São Paulo 3
Banī Suwayf 2
Boston 2
Boydton 2
Brno 2
Canberra 2
Charlotte 2
Guiyang 2
Liverpool 2
New Delhi 2
New York 2
Tokyo 2
West Jordan 2
Zapopan 2
Bangkok 1
Bertamirans 1
Buenos Aires 1
Buffalo 1
Burbach 1
Chengdu 1
Chennai 1
Chenzhou 1
Dhaka 1
Düsseldorf 1
Frankfurt am Main 1
Helsinki 1
Huntington 1
Jacksonville 1
Jining 1
Johannesburg 1
Lambeth 1
Ljubljana 1
Palo Alto 1
Philadelphia 1
Sona 1
Suffern 1
Turku 1
Venice 1
Volla 1
Washington 1
Xingtai 1
Totale 527
Salva come PNG Salva come JPEG
Nome #
Colonic Epithelial Permeability to Ions Is Restored after Vedolizumab Treatment and May Predict Clinical Response in Inflammatory Bowel Disease Patients 197
Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro-oesophageal reflux disease according to Lyon Consensus 181
Wall Thickness Ratio—A New Magnetic Resonance Parameter—Is Associated With the Outcome of Biological Therapy in Patients With Ileal and Ileocolonic Crohn’s Disease 100
Mathematical Modeling of Vedolizumab Treatment’s Effect on Microbiota and Intestinal Permeability in Inflammatory Bowel Disease Patients 92
Acid reflux episodes sensitize the esophagus to perception of weakly acidic and mixed reflux in non-erosive reflux disease patients 85
Impedance baseline and reflux perception in responder and non-responder non-erosive reflux disease patients 75
Mechanisms of action of prebiotics and their effects on gastro-intestinal disorders in adults 52
The Results From Up-Front Esophageal Testing Predict Proton Pump Inhibitor Response in Patients With Chronic Cough 34
Reflux pattern and role of impedance-pH variables in predicting PPI response in patients with suspected GERD-related chronic cough. 31
Psychological distress in inflammatory bowel disease 30
Nutritional status and bioelectrical phase angle assessment in adult Crohn disease patients receiving anti-TNFα therapy 29
Multicenter Validation of the DETAIL Questionnaire for the Screening of Spondyloarthritis in Patients With Inflammatory Bowel Diseases 25
Intra-bolus pressure and esophagogastric gradient, assessed with high-resolution manometry, are associated with acid exposure and proximal migration of refluxate 24
Reflux Patterns and Role of Impedance-pH Variables in Predicting PPI Response in Patients With Suspected GERD-Related Chronic Cough 23
Weak peristalsis with large breaks is associated with higher acid exposure and delayed reflux clearance in the supine position in GERD patients 21
Role of Mixed Reflux and Hypomotility with Delayed Reflux Clearance in Patients with Non-cardiac Chest Pain 21
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease 20
Role of Overweight and Obesity in Gastrointestinal Disease 20
Nutritional aspects in inflammatory bowel diseases 20
Adalimumab in active ulcerative colitis: A "real-life" observational study 19
Impedance-High Resolution Manometry Analysis of Patients With Nonerosive Reflux Disease 19
Role of Esophageal Motility, Acid Reflux, and of Acid Suppression in Nonobstructive Dysphagia 19
High-resolution Manometry Findings During Solid Swallows Correlate With Delayed Reflux Clearance and Acid Exposure Time in Non-erosive Reflux Disease Patients 19
Increased frequency and enhanced perception of reflux in non-erosive reflux disease patients non-responder to proton pump inhibitors 17
Understanding the relationship between esophageal motor disorders and reflux disease 17
REFLUX PATTERN AND ROLE OF IMPEDANCE-PH VARIABLES IN PREDICTING PPI RESPONSE IN PATIENTS WITH SUSPECTED GERD-RELATED CHRONIC COUGH 17
Patients With Extra-Esophageal Symptoms, Compared to NERD Patients With Typical Symptoms and Healthy Volunteers, Arc Characterized by a Higher Number of Reflux Episodes and Higher Proportion of Weakly Acidic and Mixed Reflux 16
Therapeutic drug monitoring is more cost-effective than a clinically based approach in the management of loss of response to infliximab in inflammatory bowel disease: An observational multicentre study 14
Inflammatory bowel disease course in liver transplant versus non-liver transplant patients for primary sclerosing cholangitis: LIVIBD, an IG-IBD study 12
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 11
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS‐CoV‐2 infection: an IG‐IBD study 10
Ultrasonography Tight Control and Monitoring in Crohn’s Disease During Different Biological Therapies: A Multicenter Study 10
Comparison of two strategies for the management of postoperative recurrence in Crohn’s disease patients with one clinical risk factor: A multicentre IG‐IBD study 9
Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy 9
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study 9
Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey 9
IBD Flare in the COVID-19 Pandemic: Therapy Discontinuation Is to Blame 8
Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC) 8
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study 8
Upadacitinib in Patients With Difficult-to-Treat Crohn’s Disease 6
Therapeutic adherence in inflammatory bowel disease: User guide from a multidisciplinary modified Delphi consensus 6
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning—the IG-IBD LIVE study 6
SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves 6
Totale 1.364
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.541
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.541
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202232 0 0 4 0 0 0 0 0 0 0 0 28
2022/202310 0 0 0 0 1 0 0 0 1 0 8 0
2023/202494 4 11 3 5 6 37 3 6 0 7 9 3
2024/20251.031 22 8 37 3 11 23 23 3 72 71 301 457
2025/2026197 159 38 0 0 0 0 0 0 0 0 0 0
Totale 1.364